GlobeNewswire by notified

Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care

Share

Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care

  • Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of care settings
  • First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals
  • New system simplifies workflows and equips healthcare professionals with valuable clinical insights to deliver better patient care

Basel, 12 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® pulse system in select countries accepting the CE Mark. The cobas® pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management. As an industry first, the cobas® pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities similar to that of a smartphone.

Glucose is among the most important biomarkers to assess patient health and predict, diagnose and manage metabolic disorders¹. In particular, the management of blood glucose in patients is critical to preventing acute and chronic complications that may lead to increased morbidity, mortality and healthcare costs2, 4, 5, 6. Against the backdrop of a rising epidemic of diabetes3 and other non-communicable diseases, the need to regularly perform this critical intervention adds to an ever-growing list of responsibilities facing stretched healthcare systems and professionals.

“Frontline health workers are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care,” says Thomas Schinecker, CEO, Roche Diagnostics. “Our commitment is to equip them with high-performance innovations that represent a real step change in their working lives. We are pleased to introduce a truly novel solution that puts actionable clinical insights, and a near limitless range of digital capabilities for patient care, in the palms of their hands.”

Designed for professional use in a range of care settings where timely and informed clinical decisions are needed, the cobas® pulse system introduces several advancements that aim to drastically simplify workflows for busy nurses and doctors and improve their ability to deliver care at the bedside.

For the first time in a point of care device, the cobas® pulse system is equipped with digital health applications based on the Android operating system that perform a range of clinically valuable functions – from clinical decision support to the measurement of vital signs and digital biomarkers. The Roche-selected apps are enabled by a digital platform called Smart, the newest module of the cobas® infinity edge suite of software solutions. The pairing of the cobas® pulse system with cobas® infinity edge smart marks the first integrated solution from Roche Diagnostics to leverage a pioneering business-to-business partnership model that connects developers of digital health solutions with healthcare professionals as customers. At the time of launch, Roche has already secured partnerships with several innovative companies and start-ups in the field (e.g. S4DX, imito, decide (GlucoTab), Glytec, CardioSignal, and SteadySense (SteadyTemp)).⁷

Following first commercial availability under CE Mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the cobas® pulse system in other global markets throughout 2022.

About the cobas® pulse system
The cobas® pulse system is Roche’s newest generation of connected professional blood glucose management solution, building on its legacy with Accu-Chek® Inform II. Designed with advanced safety and performance, simplicity, and enhanced digital power at its core, the cobas® pulse system serves as a gateway to the future of digital health - improving workflows and changing healthcare in favor of cost efficiency and better patient care. The cobas® pulse system is reliable, safe to use in all professional care settings (including intensive care) and with patients of all ages (including neonates). The cobas® pulse system features outstanding performance that meets the criteria of one of the latest guidelines for glucose meters⁸. It is free from interferences and features an easy-to-clean and robust design equipped for 12,000 cycles of cleaning and disinfection. The cobas® pulse system’s portability and intuitive Android-based interface make using it as simple as a smartphone. Among several other innovations, the cobas® pulse system features an illuminated glucose strip port for ease of use in poorly lit environments, wireless charging, an embedded camera for multiple uses, and secure RFID badging. Cobas® infinity edge smart equips the cobas® pulse system with Roche-selected digital health applications that enable a truly versatile range of operations for patient and workflow management.

About cobas® infinity edge suite of solutions
The Roche software solution suite called cobas® infinity edge includes three modules: unite, scribe, and smart. Used together, the solution facilitates the ability of labs and hospitals to manage patient-testing devices (Roche and non-Roche) that measure clinical health parameters anytime, anywhere. cobas® infinity edge also enables the deployment of third party applications into point of care devices. With this digital ecosystem approach, lab and hospital administrators can also better govern, update and manage use of near-patient testing devices - even remotely. The platform uses industry standard security technologies and processes to connect to electronic medical record systems (EMRs) as well as enabling remote installations, service and maintenance of devices outside the lab/hospital premises (e.g., clinics or pharmacies). This solution will bring more diagnostic capabilities - safely and securely - beyond the lab walls - closer to physicians and nurses at the points where clinical decisions are being made.

About Roche in digital healthcare
With growing investments in digital capabilities, Roche is building on its expertise in science, medicine and technology to increasingly leverage data analytic tools and novel digital technologies to transform the way healthcare is delivered and managed for each patient. Our data-driven digital solutions empower labs, healthcare providers and patients to make informed, insights-based decisions across the entire care continuum – reducing costs to society and improving patient health outcomes in the process.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Krentz AJ et al. (2016). Biomark Med. 10(11):1153-1166.
[2] Pasquel FJ et al. (2021). Lancet Diab Endocrinol 9: 174–88.
[3] DF DIABETES ATLAS (2019). Ninth edition. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Accessed September 2021.
[4] ADA Standards of Medical Care in Diabetes. (2021). Diabetes care 44: Suppl 1.
[5] Dhatariya K et al. (2020). NCBI Bookshelf.
[6] Hermanides J et al. (2010). Crit Care Med 38(3): 1430-34.
[7] S4DX, Imito, GlucoTab, Glytec, CardioSignal and STEADYTEMP
[8] CLSI POCT12-A3 Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities. Clinical and Laboratory Standards Institute, 2013.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
SileiaUrech
Phone: +41 79 935 81 48
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
KarstenKleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations

Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com


Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Stevie® Awards Announce Winners in 19th Annual International Business Awards® from Across the Globe15.8.2022 13:00:00 CEST | Press release

3,700 Nominations Were Submitted from Organizations in 67 Nations FAIRFAX, Va., Aug. 15, 2022 (GLOBE NEWSWIRE) -- High-achieving organizations and executives around the world have been recognized as Gold, Silver, and Bronze Stevie® Award winners in The 19th Annual International Business Awards®, the world's only international, all-encompassing business awards program. Winners were selected from more than 3,700 nominations submitted by organizations in 67 nations. A complete list of all 2022 Gold, Silver and Bronze Stevie Award winners by category is available at www.StevieAwards.com/IBA. More than 300 executives worldwide participated on 11 juries to determine the Stevie winners. The top winner of Gold, Silver, and Bronze Stevie Awards is HALKBANK of Istanbul, Turkey with 32. Other winners of multiple Stevie Awards include IBM Corporation (21), LLYC (20), Deutsche Post DHL (19), Abu Dhabi Ports Group (17), Viettel Group (17), OPET (15), Telkom Indonesia (13), ZER (13), Ayala Land Inc.

Bergman & Beving acquires Polartherm15.8.2022 13:00:00 CEST | Press release

Press release Bergman & Beving acquires Polartherm Bergman & Beving has today acquired 80 per cent of the shares in Polartherm Group. Polartherm is a leading player within powerful, mobile heaters for certain niches within industry, construction and aviation. Polartherm has an annual revenue of approximately MEUR 12 with good profitability. The business is based in Luvia and Kokemäki in Finland and has 57 employees. ”Polartherm has a market leading position within mobile heaters with impressive customer base within inter alia the aviation and defence sectors around the world. Our ambition with the company is now to further enhance the growth journey which the company’s management has already initiated”, says Oscar Fredell, Head of Division Tools & Consumables. “We are looking forward to joining Bergman&BevingGroup. Due to its long-term and stable position we consider it a suitable majority owner for Polartherm going forward”, says the managing director and part-owner Pasi Anttila who w

Bergman & Beving förvärvar Polartherm15.8.2022 13:00:00 CEST | Pressemelding

Pressmeddelande Bergman & Beving förvärvar Polartherm Bergman & Beving har idag förvärvat 80 procent av aktierna i Polartherm Group. Polartherm är en ledande aktör inom kraftfulla, mobila värmeaggregat för nischområden inom industri-, bygg- och flygbranscherna. Polartherm omsätter cirka 12 MEUR per år med god lönsamhet. Verksamheten är baserad i Luvia och Kokemäki i Finland och har 57 anställda. ”Polartherm har en marknadsledande position inom mobila värmeaggregat med en imponerande kundbas inom bl.a. flyg- och försvarssektorerna runtom i världen. Vårt mål med bolaget blir nu att förstärka den tillväxtresa som bolagets ledning redan påbörjat”, säger Oscar Fredell, divisionschef Tools & Consumables. ”Vi ser fram emot att bli en del av Bergman&Bevingkoncernen. Med sin långsiktiga och stabila position ser vi dem som en lämplig huvudägare för Polartherm framåt”, säger VD:n och delägaren Pasi Anttila, som fortsätter som VD och minoritetsägare i bolaget. Polartherm kommer att ingå i division

Nordic American Tankers Ltd (NYSE: NAT) – Update on contracts15.8.2022 12:36:19 CEST | Press release

Monday, August 15, 2022 Dear Shareholders and Investors, Below are the latest contracts for our suezmax ships, showing the level of the market. The rates we experience now are far above recent quarters. 12th Aug.: Vessel fixed on subjects to US Oil Major for voyage from Mediterranean to Asia. Time Charter Equivalent (TCE) about USD 60,000 over 35 days 12th Aug.: Vessel fixed on subjects to Asian interests for voyage from AG to Singapore. Time Charter Equivalent (TCE) about USD 19,000 over 36 days 4th Aug.: Vessel fixed to Asian interests for voyage cross Mediterranean. Time Charter Equivalent (TCE) about USD 40,000 over 15 days 3rd Aug.: Vessel fixed to Asian interests for voyage from Red Sea to Asia. Time Charter Equivalent (TCE) about USD 21,500 over 45 days 28th July: Vessel fixed to Asian interests for voyage from AG to Singapore. Time Charter Equivalent (TCE) about USD 46,500 over 26 days 25th July: Vessel fixed to American interests for voyage (positioning voyage) from AG to US G